Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer.
In conclusion, CYR-61 may serve as a potential target for gene therapy for the treatment of human NSCLC.
PMID: 30116327 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Gene Therapy | General Medicine | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study